Introducing the Langerhans Cell Targeted Delivery System

LC-TDS

Contributing to precision medicine.

LC-TDS

LC-TDS: The Langerhans Cell Targeted Delivery System

Easy-to-use, without injuries and highly specific – a minimal-invasive application of targeted nanoparticles.

The immune system protects our body against bacteria, viruses and other external threats to our health. A central role play dendritic cells (DCs), which recognise such pathogens, process them and train other immune cells to act against them. At the same time, DCs are also responsible tolerating the body’s own structures (autoantigens). This complex interaction is achieved by an „orchestra“ of different types of DCs.

Cutanos aims to use these mechanisms to develop both vaccines and therapies against autoimmune diseases and allergies. This is made possible by the LC-TDS, the Langerhans Cell Targeted Delivery System, which presents antigens to the immune system via just one type of DCs (Langerhans cells, LCs). The state of the LCs is decisive for the control of the immune response: if they are activated, a vaccination effect is achieved; if they remain inactive, tolerance is induced.

HOW IT WORKS

HOW IT WORKS

or how a small molecule ligand brings the system to its destination

Through this first-of-a-kind targeted delivery approach, the LC-TDS is hardly taken up by off-target cells, which promises significant dose sparing and potentially fewer side effects.

Cutanos’ LC-TDS differs from all other immunomodulating technologies due to its modular design allowing flexible adaptation for different applications. This further results in a high compatibility with other technologies. Another major advantage is the injury-free administration via the skin through minimally invasive microneedles or microinjectors, which increases application safety and patients compliance.

FIRST OF ITS KIND

FIRST OF ITS KIND

Providing exclusive access to immune cells in the epidermis

Cutanos achieves direct and minimally invasive antigen delivery to Langerhans cells via the skin – No complex and cost-intensive ex vivo loading of dendritic cells (DCs) is required!

Our LC-TDS technology also avoids the disadvantages of antibody-based targeting approaches (e.g. side effects, high production costs and blocking of the receptor for continuous antigen uptake): Due to its design, the LC-TDS mimics a natural pathogen and is processed as such by the Langerhans cells. It can be flexibly combined with various antigens and nanoparticles – often a bottleneck in non-modularly constructed drugs. This gives the LC-TDS a decisive advantage especially in vaccine development against seasonal viral pathogens (e.g. influenza or corona viruses).

PIPELINE

PIPELINE

Our research efforts emphasises on exploring the full bandwidth of immune modulation: Herein two projects are full in-house and two co-developments with pharma partners, all employing different antigen modalities in both application realms (immunity and tolerance). Further we are developing novel lipid nanoparticle (LNP) formulations optimised for mRNA delivery in skin and tailored to our LC-TDS platform. We intend to complete our Proof-of-Concept (PoC) studies by the end of 2023. These projects will then be translated into pre-clinical developments for defined indications.

WHO WE ARE

WHO WE ARE

THE FOUNDERS AND MANAGEMENT 

Dr. Robert Wawrzinek Co-Founder & CEO

Dr. Robert Wawrzinek

More Infos

Dr. Robert Wawrzinek
Co-Founder & CEO

 

Ulrich Platte, MBA CFO & CBO

Ulrich Platte, MBA

More Infos

Ulrich Platte, MBA
CFO/CBO & Managing Director

 

Prof. Dr. Christoph Rademacher Co-Founder & Advisor

Prof. Dr. Christoph Rademacher

More Infos

Prof. Dr. Christoph Rademacher
Co-Founder & Advisor

 

THE SCIENTISTS

Federica Quattrone

Federica Quattrone

More Infos

Federica Quattrone
Head of Inflammation and Infectious diseases

 

Florian Sparber Head of Tolerance and Autoimmune diseases

Florian Sparber

More Infos

Florian Sparber
Head of Tolerance and Autoimmune diseases

Klara Klein Scientist & Project Lead

Klara Klein

More Infos

Klara Klein
Scientist & Project Lead

NEWS

NEWS & MEDIA

To get the latest on Cutanos development please refer to our press releases and follow us on LinkedIn and Twitter.

New Team Member

We welcome our new

Scientist and Project Lead

Klara Klein

 

We are proud to welcome Klara to our team. With her vast expertise in immunology she is going to lead her own research project and will give valuable impacts in all of Cutanos‘ scientific endeavours!

New Team Member

We welcome our new CFO/CBO Ulrich Platte

The whole team is thrilled to announce Ulrich as our new CFO & CBO. We are beyond confident he will be a major asset to Cutanos and our next business development steps.

Welcome, Ulrich!

Cutanos and Pfizer team up

Cutanos and Pfizer team up to apply LC-TDS technology to autoimmune diseases

 

Thanks to Pfizer’s Emerging Science Fund, Cutanos will explore its immune cell-specific drug delivery system as a potential therapy platform for autoimmune disorders. In the next two years, this joint project aims to show induction of tolerance against self-antigens. Innovative therapeutic solutions in autoimmunity are one of the biggest unmet medical needs worldwide.

New Team Members!

We Welcome our Newest Team Members!

We are very happy to announce our latest additions to the team: Alexandra Sykora (Office Manager), Mirza Sarcevic and Gabriele Carta (Technical Assistants)! Welcome aboard!

Green Labs Austria

Cutanos joins Green Labs Austria Initiative 

As a biotechnology lab Cutanos feels responsible to not only contribute to science but also carrying out experiments in a more sustainable fashion. Hence, we want to participate in Green Labs Austria vision to reduce plastic waste and our carbon footprint. 


www.greenlabsaustria.at

ABA Podcast

ABA Podcast „𝗪𝗶𝗿𝘁𝘀𝗰𝗵𝗮𝗳𝘁 𝗶𝗺 ¾ 𝗧𝗮𝗸𝘁“

 

Doris Dobida talks with Cutanos‘ Co-Founder Robert Wawrzinek about starting a biotech company in Austria.

Webinar Series

Precision NanoSystems Teatime Webinar Series

Robert Wawrzinek talks about: „Small Molecule-Based Targeted Delivery of Nanoparticles to Langerhans Cells in Human Skin“

Publication – ACS central science

A Specific, Glycomimetic Langerin Ligand for Human Langerhans Cell Targeting

Eike-Christian Wamhoff, Jessica Schulze, Lydia Bellmann, Mareike Rentzsch, Gunnar Bachem, Felix F. Fuchsberger, Juliane Rademacher, Martin Hermann, Barbara Del Frari, Rob van Dalen, David Hartmann, Nina van Sorge, Oliver Seitz, Patrizia Stoitzner, Christoph Rademacher

 ACS Central Science (2019), doi.org/10.1021/acscentsci.9b00093

Publication – Biochemistry

A Liposomal Platform for Delivery of a Protein Antigen to Langerin-Expressing Cells

Jessica Schulze, Mareike Rentzsch, Donyoon Kim, Lydia Bellmann, Patrizia Stoitzner, Christoph Rademacher

Biochemistry (2019), doi.org/10.1021/acs.biochem.9b0040

Press Coverage

what the media says about Cutanos (selection)